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Abstract Six subtypes of sporadic Creutzfeldt–Jakob
disease with distinctive clinico-pathological features have
been identiﬁed largely based on two types of the abnormal
prion protein, PrP
Sc, and the methionine (M)/valine (V)
polymorphic codon 129 of the prion protein. The existence
of affected subjects showing mixed phenotypic features and
concurrent PrP
Sc types has been reported but with incon-
sistencies among studies in both results and their
interpretation. The issue currently complicates diagnosis
and classiﬁcation of cases and also has implications for
disease pathogenesis. To explore the issue in depth, we
carried out a systematic regional study in a large series of
225 cases. PrP
Sc types 1 and 2 concurrence was detected in
35% of cases and was higher in MM than in MV or VV
subjects. The deposition of either type 1 or 2, when con-
current, was not random and always characterized by the
coexistence of phenotypic features previously described in
the pure subtypes. PrP
Sc type 1 accumulation and related
pathology predominated in MM and MV cases, while the
type 2 phenotype prevailed in VVs. Neuropathological
examination best identiﬁed the mixed types 1 and 2 features
in MMs and most MVs, and also uniquely revealed the co-
occurrence of pathological variants sharing PrP
Sc type 2. In
contrast, molecular typing best detected the concurrent
PrP
Sc types in VV subjects and MV cases with kuru plaques.
The present data provide an updated disease classiﬁcation
and are of importance for future epidemiologic and trans-
mission studies aimed to identify etiology and extent of
strain variation in sporadic Creutzfeldt–Jakob disease.
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Transmissible spongiform encephalopathies (TSEs) or
prion diseases are invariably fatal neurodegenerative dis-
orders affecting humans and other mammals such as sheep,
elk, and cattle [36]. These diseases are characterized clin-
ically by a rapidly progressive neurological dysfunction
and neuropathologically by spongiform degeneration,
neuronal loss, gliosis, and sometimes by amyloid plaques,
which combine in varying degrees of severity and regional
distribution.
Biochemically, prion diseases are characterized by the
conversion of a constitutively expressed cellular protein,
the prion protein (PrP
C) into an abnormally folded, insol-
uble, partially protease-resistant isoform (PrP
Sc)[ 4, 8, 27].
Incubation of a brain homogenate from prion-infected
individuals with proteinase K (PK) under conditions lead-
ing to a complete degradation of PrP
C generates an N-
terminal truncated form of PrP
Sc, commonly referred to as
PrP27-30, an established molecular marker for the disease
[5, 38].
Sporadic Creutzfeldt–Jakob disease (sCJD), the com-
monest form of the human prion diseases, comprises a
broad spectrum of clinico-pathological variants [30]. Prion
strains are believed to be the main cause of TSE pheno-
typic diversity. Prion strains are deﬁned as isolates that
show distinct disease phenotypes upon transmission to
syngenic animals, persisting on serial transmission [6, 15,
34]. In addition, the host genotype variability in the gene
encoding PrP
C (PRNP), as determined by polymorphisms
and mutations, is another recognized causal factor for
phenotypic heterogeneity [2, 12]. The hypothesis that
PrP
Sc itself may encode strain-speciﬁc properties has
gained support over the years by the demonstration of
distinct physico-chemical subtypes of PrP
Sc that include
differences in the level of glycosylation and in the size of
proteinase K-digested PrP
Sc fragments, possibly reﬂecting
distinct protein conformations [1, 3, 9, 10, 14, 22, 28, 29,
32, 39, 41, 42]. Although the ﬁnal proof that conforma-
tional variants of PrP
Sc represent the biological basis of
prion strains is lacking, the described physicochemical
differences among PrP
Sc types are increasingly used as
surrogate markers of strain properties in a given host.
Based on differences in gel mobility and N-terminal
sequence of the core fragments (i.e. PrP27-30) generated
by PK digestion, Parchi et al. [28, 29, 32] originally
identiﬁed two major human PrP
Sc types: type 1 with a
relative molecular mass of 21 kDa and the primary
cleavage site at residue 82, and type 2 with relative
molecular mass of 19 kDa and the primary cleavage site
at residue 97. The two PrP
Sc types, in conjunction with
the codon 129 genotype, signiﬁcantly explained sCJD
phenotypic variability and provided a molecular basis for
disease classiﬁcation [7, 28, 30]. Six subtypes of sCJD
with distinctive phenotypic features were identiﬁed, each
resulting from a speciﬁc codon 129 genotype/PrP
Sc type
combination with two exceptions. MM1 and MV1 cases
were phenotypically indistinguishable and, therefore,
merged in one subtype (MM/MV 1), whereas, on the
contrary, MM2 subjects were associated with 2 subtypes
with distinctive histopathological features in the cerebral
cortex and in the thalamus and designated accordingly
(MM2-cortical or MM 2C and MM2-thalamic or MM 2T)
[30]. By showing that at least some of these sCJD sub-
types correspond to speciﬁc agent strain-host genotype
combinations, preliminary transmission studies seem to
conﬁrm the biological basis of this classiﬁcation [16, 17,
23, 42].
An important aspect of sCJD phenotypic variability,
which has not yet been investigated thoroughly, concerns
the existence of cases presenting more than one PrP
Sc type
and mixed histopathological features. This issue still
represents a potential drawback for the widespread appli-
cation of the current disease classiﬁcation for diagnostic
and epidemiologic purposes. Since the original report of
this phenomenon [30], based on the analyses of a few
samples for each brain, the co-occurrence of PrP
Sc type 1
and 2 in a percentage varying between 12 and 44% of
sCJD cases analyzed has been conﬁrmed by a number of
subsequent studies [13, 18, 20, 37, 40, 43]. In many of
them, the question of how far the proportion of cases with
concurrent PrP
Sc types is a function of the sampling pro-
tocol employed was raised. More recently, two studies
using novel antibodies recognizing an epitope between
residues 82 and 96 (i.e. not detecting type 2) found that all
type 2 samples show at least some associated protein
migrating in the 21 kDa molecular weight range and
concluded that PrP
Sc type 1 coexists in all type 2 sCJD
cases and that the number of cases with concurrent PrP
Sc
types is likely larger than previously thought [35, 45]. It
was later shown, however, that the ‘‘type 1 selective’’
antibodies fail to discriminate properly between a bona
ﬁde PK-resistant PrP
Sc core and the partially cleaved
fragments generated during digestion due to the several
PK cleavage sites included in the PrP
Sc N-terminus,
making difﬁcult the interpretation of the results obtained
[25].
To explore the issue of concurrent PrP
Sc types in sCJD
in depth, we carried out a systematic regional study in a
large series of cases. To this aim, we applied a reﬁned
western blot assay with increased sensitivity for the
detection of PrP
Sc types coexistence [25] and correlated the
molecular data with those obtained by clinical and patho-
logical examinations.
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Case and tissue selection
This study was based on 225 cases with an established
diagnosis of sCJD obtained after clinical, neuropathologi-
cal, and molecular examination. Cases of genetic and
acquired forms of CJD were excluded. The study was
restricted to cases from which large amounts of both frozen
and ﬁxed brain tissue were available. 200 patients were
obtained from a group of *240 consecutive cases referred
for diagnosis (*40 cases lacked sufﬁcient frozen tissue),
whereas the remaining 25 were speciﬁcally chosen to
increase the number of cases with mixed phenotypes. More
precisely, the 25 additional cases were selected based on
the demonstration of a mixed synaptic and perivacuolar
pattern of PrP deposition by PrP immunohistochemistry
(see ‘‘Results’’). 61 patients died in the USA between 1990
and 2001, and 164 in Europe (124 in Italy, 34 in Germany,
and 6 in Belgium) between 1993 and 2007.
Brains were removed at autopsy and either one half or
selected coronal sections of tissue, including all major
brain structures and nuclei, were immediately frozen and
stored at -80C. The remaining tissue was ﬁxed in for-
malin and was used for neuropathological examination and
PrP immunohistochemistry. Samples of frozen gray matter
(between 50 and 100 mg) for protein analysis were
obtained from the following regions: frontal (superior and
middle frontal gyri), temporal (superior and middle tem-
poral gyri), parietal (inferior parietal lobule), and occipital
(calcarine cortex and lateral occipital gyrus) cortices, hip-
pocampus (Ammon’s horn), limbic cortices (entorhinal
cortex anterior, insular cortex, and cingulate gyrus), stria-
tum (caudate and putamen nuclei), thalamus (medial and
lateral nuclei), hypothalamus, brainstem (midbrain peri-
aqueductal gray, pontine periaqueductal gray including
locus coeruleus, medullar periventricular gray), cerebellum
(hemisphere and vermis). The parietal cortex and the 3
samples from the brainstem were not available in 30 cases
from Germany. Furthermore, 1 or 2 samples were occa-
sionally lacking in some other cases [altogether 34
samples, mostly from the hypothalamus (n = 15) and
amygdala (n = 11)]. Sampling of frozen tissues was per-
formed by the same investigator (PP) according to a
deﬁned protocol across the whole series of cases. Blocks of
ﬁxed tissue were taken from the opposite half of the brain
and were used for histopathologic examination. Sampling
of ﬁxed tissues was performed by the same investigator
(PP) according to a deﬁned protocol in 160 cases. The
remaining 65 cases were sampled in Munich (Germany)
and Indianapolis (USA). In these Centers, which are both
involved in CJD National surveillance and Brain banking,
CJD brains are sampled extensively according to protocols,
which included all the areas that were of interest for this
study. Sampling of both ﬁxed and frozen tissue was per-
formed twice in a subgroup of 10 codon 129 MM subjects.
Protein analysis
Preparation of samples, Western blotting (WB), and PrP
Sc
typing were performed according to established methods
[25, 26, 33]. In particular, for the sensitive detection of
PrP
Sc types 1 and 2 concurrence, we followed the method
of Notari et al. [25]. All samples were homogenized in lysis
buffer plus at pH 6.9, digested with proteinase K (PK)
(Roche Diagnostics, speciﬁc activity by certiﬁcate of
analysis: 47.9 U/mg) at a ﬁnal concentration of 10 U/mL
and run in a 6.5 cm long separating gel. In addition,
selected samples from MV2 cases with kuru plaques (MV
2K) and MM or MV subjects showing mixed pathological
features but only PrP
Sc type 1 after the run in the 6.5 cm
long gel were also run in a 15 cm long gel. To this aim, at
least one sample from each cortical lobe was re-analyzed.
All immunoblots were probed with the monoclonal anti-
body 3F4 with epitope at PrP residues 108-111 at 0.1 lg/
ml concentration (Signet Labs, MA, USA). In addition,
immunoblots were probed with the monoclonal antibody
1E4 with epitope mapped at PrP residues 98–100 at 2 lg/
ml concentration (Sanquin Reagents, Amsterdam, The
Netherlands) in the following cases: (a) all samples from
VV1 cases; (b) 20 neocortical samples from 10 MM1 cases
with pure synaptic PrP deposition, and (c) all samples from
30 MM or MV cases, which showed a mixed pattern of PrP
deposition by immunohistochemistry and either no evi-
dence or a very scanty and focal (1 or 2 areas) type 2
accumulation after immunoblotting with the 3F4 antibody.
Finally, selected blots from MV 2K samples were also
probed with SAF60 against PrP residues 157–161, at
0.4 lg/ml.
We quantitatively calculated the ratio between type 1
and type 2 in the non-glycosylated PrP
Sc after densito-
metric analyses of immunoblots probed with 3F4 using the
AIDA Image Analyzer software (RayTest). This choice
was in part driven by our experience indicating that
deglycosylation is associated to a loss of deﬁnition in the
type 1 (21 kDa) and type 2 (19 kDa) bands which makes
their distinction and relative quantitation less reliable.
Furthermore, given that it has been previously shown [28,
30] that the relative abundance of glycosylated versus non-
glycosylated PrP
Sc shows only relatively minor differences
among the sCJD subtypes associated to either PrP
Sc type 1
or PrP
Sc type 2, we assumed that the analyses of the
unglycosylated form would be representative of the whole
protein. We tested this hypothesis by comparing densito-
metric analyses of non-glycosylated glycoforms versus
deglycosylated preparations from representative regions of
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2. Overall, we found that, compared to the latter, the ﬁrst
approach is associated to a relatively minor overestimation
of type 2 protein. In particular, the difference was almost
negligible for the group of samples with dominant type 1
(69/31% on non-glycosylated isoforms vs. 72/28% after
deglycosylation, n = 20), and slightly more evident in the
group of samples with dominant type 2 (29/71% on non-
glycosylated isoforms vs. 37/63% after deglycosylation,
n = 30).
To express quantitatively with a single number the rel-
ative amount of type 1 and type 2 in a given case (total type
1 or type 2 ‘‘load’’) we calculated the mean of the relative
amounts of either type 1 or type 2, expressed in % of total
PrP
Sc signal, in the different brain regions examined.
Molecular genetic analysis
Genomic DNA from all subjects was used to amplify the
coding region of PRNP in the polymerase chain reaction
(PCR). PRNP open reading frame was ampliﬁed as previ-
ously described [11]. The PCR product was visualized on a
1% agarose gel to detect potential insertion mutations or
deletions. Potential point mutations were revealed by
dHPLC analyses. Mutations were also ruled out by direct
sequencing of PRNP open reading frame in about 50% of
cases. Finally, the codon 129 genotype was examined by
digestion with the restriction endonuclease Nsp 1.
Neuropathology
Semiquantitative evaluation of spongiosis and gliosis was
carried out in all cases by comparing hematoxylin and
eosin stained sections obtained from the same 21 brain
regions evaluated biochemically. Spongiosis was rated on a
0–4 scale (not detectable, mild, moderate, severe, and
status spongiosis), whereas gliosis was scored on a 0–3
scale (not detectable, mild, moderate, and severe). A lesion
proﬁle for each patient was obtained by averaging the two
scores.
For PrP immunohistochemistry, parafﬁn sections from
formalin-ﬁxed and formic acid treated blocks of the areas
selected for neuropathologic examination were processed
using the monoclonal antibodies 3F4, according to pub-
lished protocols [30]. PrP deposits were described as
diffuse or synaptic, perivacuolar, coarse or patchy and
plaque-like.
Clinical analysis
Clinical data were available in most cases, and medical
records always included at least one neurological exami-
nation. Duration of symptoms was calculated from the time
of presentation of neurological signs suggesting an organic
cause. Prodromal symptoms were not taken into account.
Clinical signs were classiﬁed ‘‘at onset’’ when observed
within the ﬁrst quarter of the mean duration of symptoms
of the group to which the patient belonged (i.e. 1 month if
the mean duration was 4).
Results
PrP
Sc detection and typing
In the present study, we tried to maximize the detection
sensitivity of PrP
Sc type co-occurrence in sCJD-affected
brains. At variance with previous studies, we typed PrP
Sc
after a detailed topographic analysis of 21 brain regions
and using the method recently described by Notari et al.
[25], which has shown increased sensitivity for the detec-
tion of bona-ﬁde concurrence of PrP
Sc types 1 and 2.
Furthermore, we probed selected immunoblots with 1E4, a
recently characterized monoclonal antibody with a higher
afﬁnity for type 2 than for type 1 [44]. The latter approach
allowed us an increased protein loading in the gel and a
better identiﬁcation of PrP
Sc type 2 when present in rela-
tively low amounts (Fig. 1a) in the protein types mixture.
The results obtained in the largely unselected series of
200 cases after using both 3F4 and 1E4 antibodies are
shown in Table 1. The overall prevalence of PrP
Sc types 1
and 2 concurrence was 35% (32% when only the results
with 3F4 were considered). The same incidence of mixed
cases was also found in the two largest groups of subjects
from Italy and USA when considered individually.
Although the protein mixture was detected in each codon
129 genotype (Fig. 1b), PrP
Sc types 1 and 2 co-occurred
more frequently in MM than in MV or VV subjects. A
PrP
Sc proﬁle comprising two distinct bands also charac-
terized the MV2 subtype with kuru plaques (MV 2K) in
many brain regions, but the relative size of the associated
band (i.e. 20 kDa) distinguished these proﬁles from bona-
ﬁde types 1 and 2 concurrence (Fig. 1b), as previously
shown [24, 25].
Regional variation and relative ‘‘load’’ of PrP
Sc Types 1
and 2 concurrence
MM subjects
The regional distribution of co-existing PrP
Sc types 1 and 2
in MM subjects reproduced features previously observed in
the pure MM1 and MM2-cortical (MM 2C) sCJD subtypes
[30], although quantitatively the relative proportion of type
1 and type 2 accumulation in these cases varied exten-
sively. Most cases had PrP
Sc type 1 in all areas and PrP
Sc
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thalamus (Fig. 2a), whereas only a small group of subjects
showed a predominant PrP
Sc type 2 ‘‘load’’ (Fig. 2b). The
two groups will be indicated as MM 1?2C and MM 2C?1
throughout the manuscript, MM 2C?1 being deﬁned as a
case in which the mean total amount of type 2 (total type 2
‘‘load’’) expressed in % of total PrP
Sc signal and calculated
by averaging the results obtained from all brain regions
examined, is higher than that of type 1 (i.e.[51%).
The detailed regional PrP
Sc typing in the MM 1?2C
group provided the following results. When 3F4 was used,
74% of cases showed type 2 in 7 or fewer of the 21 regions
analyzed, and 42% of them in only 1 or 2 (Fig. 3). In the
latter group, 3F4 detected the PrP
Sc types mixture only in
the cerebral cortex or thalamus in 37 of the 504 samples
analyzed (Fig. 3). However, when 1E4 was used, the
number of mixed samples in the cerebral cortex or thala-
mus raised about 2.6 times to 98 (data not shown).
Noteworthy, the number of cases showing type 2 in only
one or two areas dropped from 24 to 8. Furthermore, 1E4
detected PrP
Sc type 2 in 6 out of 7 subjects in which 3F4
failed to demonstrate the type 2 protein despite its presence
was strongly suggested by the results of PrP immunohis-
tochemistry (see below). Finally, in the remaining samples
from subcortical areas, 1E4 conﬁrmed the results obtained
with 3F4 and failed to reveal a signiﬁcant type 2
accumulation.
In the group of MM 1?2C with type 2 in up to 7 brain
regions (i.e. 74% of cases), the amount of PrP
Sc type 1 was
higher than that of type 2 in 84% of the mixed samples,
while type 2 had a stronger signal than type 1 in the
remaining 16%. The mean total type 2 ‘‘load’’ in this
group, calculated on immunoblots probed with 3F4, was
3.4% (range 0.6–14%).
The remaining 26% of MM 1?2C cases showed a more
widespread PrP
Sc type 2 accumulation involving from 10 to
16 different brain regions. In this group, PrP
Sc type 1 was
predominant over type 2 in 43% of the mixed samples,
while type 2 had a stronger signal than type 1 in the
remaining 57%. The mean total type 2 ‘‘load’’, again cal-
culated on immunoblots probed with 3F4 raised to 30%
(range 18–38%).
The study of the regional protein distribution in MM
1?2C subjects showed that PrP
Sc type 2 was overall more
frequently seen in the cerebral cortex than in subcortical
areas (Fig. 3). The temporal, parietal, and occipital neo-
cortices were the cortical areas which preferentially
accumulated the type 2 protein (Fig. 3). Among subcortical
areas, the thalamus was by far the most frequent site of
type 2 accumulation, whereas the brainstem and, to a
greater extent, the cerebellum (Fig. 3) were the regions
with the lowest frequency (1 and 0 cases, respectively) of
type 2 detection.
At variance with MM 1?2C cases, in MM 2C?1 sub-
jects type 2 was the only detectable protein species in some
areas (Fig. 2b, Table 2) and its amount was higher than
that of type 1 also in most areas where the two proteins
coexisted (Table 2).
Table 1 PRNP genotype and PrP
Sc type in a unselected series of 200
sCJD cases
Type
a MM MV VV Total
Type 1 67 (52) 2 (6) 2 (5) 71 (35)
Types 1?2 concurrence 56 (43) 7 (23)
b 6 (15) 69 (35)
Type 2 6 (5)
b 22 (71)
b 32 (80) 60 (30)
Total 129 31 40 200
MV 1?2 includes 2 cases with kuru plaques and 5 without, MM2
includes 4 MM 2T, and 2 MM 2C cases, whereas MV2 includes 20
cases with kuru plaques and 2 without
% are expressed in brackets and refer to each single column
a Typing results refer to both 3F4 and 1E4 mAbs
b Phenotypically heterogenous patient groups
Fig. 1 a mAb 1E4 shows a relative higher afﬁnity for PrP
Sc type 2
than for PrP
Sc type 1. Western blot proﬁles of PrP
Sc from 3 sCJD MM
subjectsshowingvariousrelativeproportionsofPrP
Sctype1andtype2.
Each sample has been loaded twice at the same concentration and
probed either with 3F4 (left) and 1E4 (right). Lane 1 sample with
dominant type 1 and only 3–5% of type 2; Lane 2 sample with 60/
40% type1/type2 ratio; Lane 3 sample with pure type 2. b Western
blot proﬁles of PrP
Sc (3F4 antibody) from sCJD subjects with
concurrent PrP
Sc types 1 and 2 carrying different codon 129 PRNP
genotypes (lanes 2–4). PrP
Sc type 1 from a MM1 case (lane 1), and
PrP
Sc type 2 from a VV2 case (lane 6) are included as controls. The
PrP
Sc proﬁle associated with the sCJD MV2 phenotype with kuru
plaques (sCJD MV2K) is shown in lane 5. The upper band of the
PrP
Sc doublet in lane 5 migrates faster than the type 1 band. Frontal
cortex homogenates were treated with PK and probed with 3F4.
Approximate molecular masses are in kilodaltons
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PrP
Sc types 1 and 2 concurrence in MV cases was detected
in two phenotypically distinct groups of subjects. The
absence or presence of kuru plaques best distinguished the
two groups. In subjects lacking kuru plaques, the con-
currence of PrP
Sc types reproduced the features seen in
MM 1?2C subjects. At variance with the MM group,
however, the relative proportion of MV 1?2C and MV
2C?1 was signiﬁcantly different. Indeed, only one case
had type 1 in all brain regions and the concurrent type 2
in 5, two had 12 and 14 areas with a mixed molecular
phenotype, respectively (but a predominant type 1 load),
while the remaining 3 showed a predominant type 2
accumulation (Table 3).
PrP
Sc types 1 and 2 concurrence was more difﬁcult to
assess in MV subjects with kuru plaques (i.e. MV 2K
subtype) because of the presence of the 20 kDa band
(Fig. 1), which we detected in virtually all samples from
subcortical structures and in 75% of those taken from the
neocortex (data not shown). Thus, a relatively weak
21 kDa signal cannot be considered proof of bona-ﬁde
PrP
Sc type 1 concurrence, since it would also be compatible
with a partially cleaved fragment of the 20 kDa PrP
Sc core
[25]. As a consequence, we considered the 21 kDa band a
bona-ﬁde type 1 only when its intensity was similar or
higher than that of the 20 kDa fragment. Using these
stringent criteria, we detected an undisputable type 1 signal
in a least two cortical samples in only 2 of the 24 MV 2K
cases analyzed (data not shown). Interestingly, at variance
with the other MV 2K cases, the PrP
Sc proﬁle in these two
cases included the so called 13 kDa CTF (C-terminal
truncated fragment) (data not shown), which at variance
with MV 2K is consistently found in both MM1 and VV1
cases [26].
Fig. 2 Western blot proﬁles of
PrP
Sc (3F4 antibody) from
different brain regions of a one
sCJD MM 1?2C subject
showing the type 2 protein only
focally in the cerebral cortex
(arrowheads) and b one sCJD
MM 2C?1 subject showing a
widespread PrP
Sc type 2
accumulation, a focal deposition
of the type 1 protein
(arrowheads) in the cerebral
cortex, putamen, and thalamus,
and a dominant type 1 in the
cerebellum. Areas shown
include the middle frontal gyrus
(MFG), middle temporal gyrus
(MTG), parietal cortex (PC),
lateral occipital cortex (OCC2),
insular cortex (INS), putamen
nucleus (PUT), medial thalamic
nuclei (TH1), and cerebellum
(CE). Approximate molecular
masses are in kilodaltons
Fig. 3 Prevalence and regional distribution of PrP
Sc type 2 in a series
of 57 MM 1?2C subjects. PrP
Sc type 1 was detected in all areas.
Subjects are divided in 3 groups based on the number of areas with a
detectable PrP
Sc type 2 signal on WB. For each group, the % of type 2
positive samples in each brain region is shown. The mean total type 2
‘‘load’’ foreach group, asdeﬁned in ‘‘Materials andmethods’’, is given
in brackets. FC frontal cortex, TC temporal cortex, PC parietal cortex,
OCC occipital cortex, Limbic CTX limbic cortices, Hipp ? AMG
hippocampus?amygdala, STR striatum, HYP hypothalamus, TH
thalamus, BRST brainstem, CE cerebellum
664 Acta Neuropathol (2009) 118:659–671
123VV subjects
Six VV cases with concurrent PrP
Sc types 1 and 2 were
found. PrP
Sc type 2 was always dominant and detectable in
almost all samples. By contrast, type 1 was only present
focally in the cerebral cortex, in the striatum or in both. In
two cases, however, PrP
Sc type 1 was seen in most samples
from cerebral cortex and striatum and in a single case, it
showed an even more widespread accumulation involving
all the cerebral cortical samples, the striatum, amygdala,
hippocampus, hypothalamus and thalamus (Fig. 4a). When
concurring, type 2 was predominant over type 1 in 76% of
samples, while type 1 had a stronger signal than type 2 in
the remaining 24%. The mean total type 1 ‘‘load’’ in VV
2?1 was 9.4% (range 1.5–38%).
Although clearly distinguishable from a type 1 and 2
concurrence, also the PrP
Sc type 2 proﬁle in VV subjects
was sometimes characterized by a doublet comprising a
*18.5 kDa fragment in addition to the typical 19 kDa
band (Fig. 4b). These two bands concurred in the cere-
bellum in all cases, in the thalamus in 50% of them and in
the midbrain in 18%. Since epitope mapping indicated that
the 18.5 peptide, like the 19 kDa fragment, has an intact C-
terminus (data not shown), the two fragments likely differ
in their N-terminal PK cleavage site (i.e. the 18.5 fragment
is further cleaved beyond residues 97–99).
Molecular-phenotypic correlations: the pathological
phenotype
The pathological phenotype in MM/MV 1?2C and MM/
MV 2?1C subjects displayed varying relative amounts of
features as previously described in the pure MM/MV 1 and
MM/MV 2C subtypes [30, 33]. The lesion proﬁle in MM/
MV 1?2C largely overlapped with that of pure MM/MV 1
cases, with the exception of the cerebellum, which was less
affected relatively to the cerebral cortex (Fig. 5, and data
not shown). Histopathologic hallmarks in these cases were
(a) ‘‘morula-like’’, sometimes referred to as ‘‘grape-like’’,
conﬂuent foci of spongiform degeneration with large vac-
uoles in addition to the classic microvacuolation, and (b) a
mixed synaptic/perivacuolar or coarse pattern of PrP
deposition (Fig. 6a, b). With the exception of one case, in
which, only the type 1 protein could be demonstrated by
immunoblotting even after the 1E4 staining, in this group
we found a 100% correlation between the large vacuoles
and the perivacuolar staining on one hand and the PrP
Sc
type 2 detection by immunoblotting on the other. The
extension of the perivacuolar or coarse PrP staining, co-
localizing with the conﬂuent vacuoles varied signiﬁcantly
from case to case and was overall more common in the
cerebral cortex than in subcortical areas (Fig. 7). The
temporal, parietal and occipital cortices were the most
Table 2 Regional relative amounts (in % ± SD) of PrP
Sc type 2 in MM 2C?1 subjects (N = 5)
Brain region Type 1 only Type 1[2 Type 2[1 Type 2 only
Neocortex (0) 38 ± 11 (14) 70 ± 18 (46) (40)
Limbic areas (0) 41 ± 3 (16) 77 ± 9 (44) (40)
Striatum (0) 42 ± 8 (20) 78 ± 14 (70) (10)
Thalamus (0) 44 (10) 90 ± 7 (70) (20)
Hypothalamus ? Brainstem
a (21) 44 ± 4 (14) 75 ± 14 (43) (22)
Cerebellum (70) 38 (10) 61 ± 4 (20) (0)
Numbers in brackets express the % of samples showing each of the 4 proﬁles in the listed brain regions
a Samples from the brainstem were not available in three cases
Table 3 Regional relative amounts (in % ± SD) of PrP
Sc type 2 in MV 2C?1 cases (N = 3)
Brain region Type 1 only Type 1[2 Type 2[1 Type 2 only
Neocortex (0) 48 (5) 84 ± 12 (47) (48)
Limbic areas (0) 48 (7) 80 ± 15 (73) (20)
Striatum (0) 33 ± 13 (50) 75 ± 14 (50) (0)
Thalamus (0) 46 (17) 83 ± 4 (83) (0)
Hypothalamus ? Brainstem (8) 32 ± 10 (44) 65 ± 12 (25) (0)
Cerebellum (33) 7 (17) (0) (50)
Numbers in brackets express the % of samples showing each of the 4 PrP
Sc proﬁles in the listed brain regions
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123affected cortical areas (Fig. 7). Among subcortical struc-
tures, the thalamus most often showed the perivacuolar
staining, whereas the brainstem and to a greater extent the
cerebellum (Fig. 7) were the areas with the lowest
frequency.
The pathological phenotype of MM/MV 2C?1 largely
overlapped to that of MM/MV 2C subjects. However, as a
distinctive feature from the pure MM/MV 2C phenotype,
all these cases had a synaptic pattern of PrP staining in the
cerebellum, which well correlated with the presence of
PrP
Sc type 1 on western blots.
The lesion proﬁle and the pattern of PrP staining in all 6
VV subjects with concurrent PrP
Sc types (VV2?1) were
very similar to those of typical VV2 sCJD cases. As the
only distinctive feature, the two cases with the most sig-
niﬁcant type 1 accumulation showed a less consistent
laminar pattern of spongiform degeneration in the cerebral
cortex and a milder cerebellar pathology when compared to
VV2 cases with similar disease duration.
Lastly, the two MV 2K?1 cases had no clear distin-
guishing pathological features although they both showed a
relatively mild pathology and the lack of a laminar pattern
of spongiform degeneration in the cerebral cortex. Of
notice, however, we observed a perivacuolar pattern of
PrP
Sc deposition co-localizing with the presence of larger
vacuoles in 6 out of 25 of the sCJD MV 2K subjects
(Fig. 6c, d) as well as in one MM2-thalamic (MM 2T) case.
The regional distribution of the perivacuolar staining was
not distinguishable from that observed in MM/MV 1?2C
and mainly involved samples from the cerebral cortex (data
not shown).
Molecular-phenotypic correlations: clinical features
MM/MV 1?2C and MM/MV 2C?1 subjects showed a
signiﬁcant difference in both disease duration and fre-
quency of symptoms at onset according to the relative load
Fig. 4 a Western blot proﬁles
of PrP
Sc (3F4 antibody) from
different brain regions of the
sCJD VV 2?1 subject with the
more signiﬁcant type 1
deposition. Areas shown include
the middle frontal gyrus (MFG),
middle temporal gyrus (MTG),
parietal cortex (PC), lateral
occipital cortex (OCC2), insular
cortex (INS), putamen nucleus
(PUT), medial thalamic nuclei
(TH1), and cerebellum (CE).
Approximate molecular masses
are in kilodaltons. b Western
blot proﬁles of PrP
Sc doublets in
sCJD VV2, sCJD MM 1?2 and
sCJD MV 2K. Lanes 1 and 2
show the association of a
*18.5 kDa fragment with the
typical 19 kDa type 2 band in
sCJD VV2 cerebellum (CE,
V = vermis, H = hemisphere).
Approximate molecular masses
are in kilodaltons
Fig. 5 Relative severity of lesions (i.e. spongiform degeneration and
astrogliosis) in the cerebral cortex (mean of scores in neocortical and
limbic cortical areas) and cerebellum: comparison between MM/MV
1( n = 65), MM/MV 1?2C (n = 63), MM/MV 2C?1( n = 9), and
MM/MV 2C (n = 4) sCJD groups. The line slope expresses the ratio
between the degree of cortical and cerebellar pathology. Group MM/
MV 1?2C* includes only the cases within the MM/MV 1?2C group
showing type 2 in at least 5 areas (n = 17)
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123of the two protein types (Tables 4, 5). Clinical signs in
MM/MV 1?2C with a limited PrP
Sc type 2 deposition (up
to 5 brain regions involved) did not signiﬁcantly differ
from those of MM/MV 1, but the disease duration became
signiﬁcantly longer and cerebellar signs less frequent at
onset with increasing type 2 load. Thus, MM/MV 2C?1
subjects showed both a disease duration and relative fre-
quency of symptoms at onset consistent with those of sCJD
MM/MV 2C. Age at onset and disease duration in VV 2?1
subjects were consistent with those of sCJD VV2, but the
relative frequency of cognitive decline at onset was higher
than in VV2 cases, although the difference was not statis-
tically signiﬁcant, probably because of the low number of
VV 2?1 cases. Last, clinical features in the 2 MV 2K?1
subjects were within the spectrum of the MV 2K group.
Discussion
Previous studies have addressed the issue of PrP
Sc types 1
and 2 co-occurrence in sCJD. Most of them raised the
question of the inﬂuence of the number of cases and brain
areas analyzed and emphasized the possibility that the co-
occurrence of PrP
Sc types 1 and 2 is underestimated [13,
18, 20, 30, 37, 40, 43]. On the other hand, the use of a
novel, potentially very sensitive approach, later shown to
have pitfalls related to the detection of unspeciﬁc bands
Fig. 6 a A ‘‘grape-like’’ focus
of spongiform degeneration
with large conﬂuent vacuoles
surrounded by typical
spongiform degeneration with
ﬁne, relatively small vacuoles in
sCJD MM 1?2C (hematoxylin
and eosin 9200, frontal cortex);
b focal perivacuolar staining
surrounded by a synaptic pattern
of PrP immunoreactivity
(9200) in the cerebral cortex
of a sCJD MM 1?2C;
c spongiform degeneration with
large vacuoles (hematoxylin and
eosin 9200) and d perivacuolar
PrP deposition (9200) in the
cerebral cortex of a sCJD MV
2K
Fig. 7 Regional distribution of the coarse/perivacuolar pattern of
PrP
Sc deposition in 40 MM/MV 1?2C cases divided in 3 groups
according to the number of regions showing the perivacuolar pattern
in individual cases. For each group, the % of cases revealing the
perivacuolar pattern in each brain region is shown. FC frontal cortex,
TC temporal cortex, PC parietal cortex, OCC occipital cortex, Limbic
CTX limbic cortices, Hipp ? AMG hippocampus?amygdala, STR
striatum, HYP hypothalamus, TH thalamus, BRST brainstem, CE
cerebellum
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123generated by partially digested PrP
Sc fragments [25], likely
led other investigators to overestimate the incidence of the
concurrent PrP
Sc types [35, 45]. Thus, the overall results
on the phenomenon of the coexistence of molecular and
clinico-pathological sCJD subtypes are at present incon-
clusive with respect to incidence, effect on disease
phenotype and criteria for disease classiﬁcation. To con-
tribute to the full understanding of these issues, in the
present study, we combined a systematic analysis of sev-
eral brain regions in a large series of case including all
codon 129 genotypes and the rarest phenotypes with the
use of a reﬁned methodology for the detection of the PrP
Sc
type concurrence, which provides good sensitivity com-
bined with high speciﬁcity [25].
After screening about 4,200 samples from a largely
consecutive series of 200 cases, we estimated that PrP
Sc
types 1 and 2 coexist in about 35% of sCJD cases, which is
overall consistent with ﬁgures from some of the previous
studies [13, 37, 43] in which the number of cases and areas
analyzed were signiﬁcantly lower. This ﬁnding supports
the idea that PrP
Sc types co-occurrence involves a relevant
but limited group of sCJD subjects and indicates that the
incidence of the phenomenon had not been signiﬁcantly
underestimated.
As far as the characteristics of the CJD population with
mixed phenotypes are concerned, our data show that the
PrP
Sc types 1 and 2 co-occur more frequently in the MM
than in the MV and VV genotypes. More speciﬁcally, the
large majority of sCJD cases with concurrent PrP
Sc types
combines features of the MM and MM 2C sCJD subtypes,
in variable proportions. Most commonly, in such cases, the
MM1 phenotype is predominant over the MM 2C pheno-
type, but the opposite situation also rarely occurs. The
latter results signiﬁcantly differ from those obtained in
most previous studies. Indeed, Head et al. [13] mainly
found a focal type 1 co-occurrence in MM and MV sub-
jects with dominant type 2, Schoch et al. [40] detected the
mixed protein types mostly in MV2 cases showing the type
1 only focally in subcortical areas, and Uro-Coste et al.
[43] mainly detected a random co-occurrence of type 1 in
MV or VV cases with dominant type 2. Given that only our
study was based on a large series of consecutive cases, we
attribute such heterogeneity of previous results to case
selection biases, although methodological differences may
also have contributed [43].
Since subjects with mixed PrP
Sc types represent a
signiﬁcant proportion of the sCJD population, show
distinctive phenotypic features, and potentially represent a
Table 4 Demographic characteristics and classiﬁcation of patients
sCJD groups MM/MV 1 MM/MV 1?2C MM/MV 2C?1 MM/MV 2C MV 2K
a VV 1 VV 2?1V V 2
No. cases 66 63 9 4 26 5 6 39
Age at onset (years) 70.1 (48–86) 68.6 (42–89) 65.3 (53–72) 67.8 (61–75) 65.4 (48–81) 39.3 (24–49) 69.3 (59–85) 64.5 (45–83)
Duration* (months) 4.0 (1–24) 4.0 (1–26) 18.1 (6–33) 20.0 (12–36) 15.8 (5–48) 15.3 (14–16) 6.5 (3.5–13) 6.3 (3–18)
a Includes 2 cases with MV 2K?1
* p\0.001 between MM/MV 1?2C and MM/MV 2C?1 or between MM/MV 1 and MM/MV 2C?1 (Wilcoxon rank sum test)
Table 5 Symptoms at disease onset (in %) in the sCJD subgroups
sCJD Groups MM/MV 1 MM/MV 1?2C MM/MV 2C?1 MM/MV 2C MV 2K
a VV 1 VV 2?1V V 2
No. of cases 66 63 17
b 9 4 26 5 6 39
Cognitive 74 71 76 89 100 54 100 66 25
Gait or limb ataxia
§ 51 28 12 0 0 85 0 100 100
Visual central 32 27 35 22 0 4 0 0 0
Aphasia 15 19 18 33 25 4 20 0 0
Myoclonus 8 0 0 0 0 0 0 0 0
Psychiatric 12 11 17 0 0 0 0 0 2
Pyramidal 6 0 0 0 0 0 0 0 0
Sensory 2 3 0 0 0 12 0 0 5
Other diskynesias 3 2 6 0 0 8 0 0 0
Oculomotor 2 3 0 0 0 0 0 0 18
a Includes 2 MV 2K?1 cases
b Includes only the cases in which PrP
Sc type 2 was detected in at least 5 areas
§ p\0.005 between MM/MV1 and MM/MV 1?2C with more than 5 areas with type 2 and p\0.002 between MM/MV 1 and MM/MV 2C?1
(Fisher exact test)
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123distinct subtype in terms of biological relevance, it is
important that they are properly identiﬁed and are added as
new subtypes in the current sCJD classiﬁcation (Table 6).
Despite the emphasis on molecular features of current
sCJD classiﬁcation, it has become increasingly clear that
PrP
Sc typing alone, when limited to a single or even a few
brain samples, fails to provide an accurate classiﬁcation in
a signiﬁcant proportion of cases. This is mainly related to
the focal nature of the ‘‘mixed features’’ in many sCJD
cases with PrP
Sc types 1 and 2 concurrence. Indeed, we
would have misclassiﬁed the disease subtype in about
27.5% (using 3F4) of cases with MM or MV genotype, if
we had analyzed PrP
Sc only in the frontal cortex, the area
more commonly used for typing worldwide. For the same
reason, discrepancies may arise when PrP
Sc-typing and PrP
immunohistochemistry are performed from individual
samples taken from opposite hemispheres or even adjacent
cortical gyri. However, our study shows that the regional
deposition of either type 1 or type 2 when concurrent is not
random and that a relatively limited number of critical
brain structures must be assessed to reach an accurate
classiﬁcation. Furthermore, our results further underline the
importance of applying both molecular and neuropatho-
logical assessment for sCJD subtype classiﬁcation. In this
regard, the lack of detection of PrP
Sc type 2 in a minority of
MM subjects, despite the presence of a mixed synaptic and
perivacuolar pattern of PrP deposition, indicates that when
type 2 is very focal or limited in amount, histopathologic
examination is more sensitive in identifying such cases
than PrP
Sc typing, at least when only the 3F4 antibody is
used. Given the very strong correlation in MM subjects
between PrP
Sc type 2 detection and the large ‘‘grape-like’’
vacuoles and the perivacuolar pattern of PrP deposition on
histopathologic examination, which is in line with results
previously obtained in other studies [18, 37], we propose
that these cases are classiﬁed as MM 1?2C or MV 1?2C
even without the ﬁnal proof of type 2 detection by western
blot. Alternatively, PrP
Sc typing using the antibody 1E4
was in our hand as sensitive as the histopathologic exam-
ination in the detection of cases with very focal type 2.
In the light of the present results, the most important
regions to be assessed pathologically include the cerebral
cortex from each of the 4 lobes, the striatum, hippocampus,
thalamus and cerebellum. The cerebellum, in particular, is
critical for the recognition of the synaptic pattern of PrP
deposition as marker of PrP
Sc type 1 concurrence in the
cases with dominant type 2.
Taken together, our data indicate that a protocol
including the neuropathologic assessment of the eight brain
regions mentioned above and PrP
Sc typing in four critical
regions such as the temporal, parietal and occipital neo-
cortices, and medial thalamus is strongly recommended for
a reliable sCJD group classiﬁcation addressing the issue
of mixed phenotypes. Indeed, by applying this protocol
Table 6 Nomenclature and classiﬁcation of sCJD subtypes
Nomenclature
a %
b Distinctive histopathologic features
Pure subtypes
MM/MV 1; VV2; MV 2K;
MM/MV 2C; MM 2T; VV1;
65 Previously established [30] (for a summary see Table 8 in [30])
Mixed subtypes
MM/MV 1?2C 26 As in MM/MV 1 but with clusters of large vacuoles associated
to perivacuolar and coarse PrP deposition mainly in cerebral
cortex or thalamus
MM/MV 2C?1 2 As in MM/MV 2C but with synaptic-type PrP staining in the
molecular layer of the cerebellum
VV 2?1 3 Virtually indistinguishable from VV2
MV 2K?1 1 Virtually indistinguishable from MV 2K
MV 2 K?C 3 As in MV 2K but with clusters of large vacuoles associated to
perivacuolar and coarse PrP deposition mainly in cerebral
cortex
MM 2 T?C \1 As in MV 2T but with clusters of large vacuoles associated to
perivacuolar and coarse PrP deposition mainly in cerebral
cortex
a It is largely based on codon 129 PRNP genotype, which can be either methionine (M) or valine (V) and the PrP
Sc type (1 or 2 according to
Parchi et al. [28, 29]). Since both MM 2 and MV 2 groups are associated to 2 distinct phenotypes, these are further deﬁned with a third parameter
(capital letter) referring to distinctive histopathological features: K kuru type amyloid plaques, C predominant cortical pathology with conﬂuent
vacuoles and perivacuolar PrP staining, T prominent thalamic pathology with atrophy
b Percentage of total consecutive sCJD cases (n = 200) investigated
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123instead of examining all 21 brain regions, we would have
reached the same classiﬁcation of cases in the present
series.
We also wish to underline the importance of identifying
correctly the sCJD cases with mixed features for trans-
mission purposes. Indeed, the question of whether the
concurrence of PrP
Sc types 1 and 2 in CJD reﬂects a co-
infection by two prion strains related to speciﬁc undis-
covered human genotypes, or determined by epigenetic
factors remains unanswered and will largely rely on
transmission studies in which the careful selection of
samples will be of critical importance. Concerning this
critical question, we ﬁnd intriguing that the large, conﬂuent
vacuoles and the perivacuolar pattern of PrP
Sc deposition,
we originally linked to sCJD MM 2C are also found in a
subgroup of MV 2K subjects in addition to MM/MV
1?2C. In addition, we have described here the same
morphological features in one case of fatal insomnia (i.e.
the MM2-thalamic subtype or MM 2T) which adds to two
previously reported cases [19, 30, 31]. Thus, it seems that
large conﬂuent vacuoles and the perivacuolar pattern of
PrP
Sc deposition may be found in sCJD associated with all
phenotypes linked to MM or MV at codon 129. Although
this observation remains difﬁcult to interpret at present, it
appears relevant for our future understanding of the
molecular basis and the extent of strain variation in sCJD.
In any case, our observation strongly suggests that the
phenomenon of mixed phenotypes in sCJD goes beyond
PrP
Sc types 1 and 2 coexistence and also involves subtypes
which shares the same PrP
Sc type. This, in turn, further
underlines the importance of combining histopathological
assessment and biochemical PrP
Sc typing for sCJD subtype
characterization.
The present data also show that the association of two
PrP27-30 fragments, which does not represent a bona-ﬁde
type 1 and 2 concurrence, may also be a feature of some
sCJD cases. Thus, the PrP27-30 proﬁle in VV2 cases in the
cerebellum, thalamus and midbrain is sometime character-
ized by a doublet comprising a 18.5 kDa in addition to the
typical 19 kDa band, while the western blot proﬁle of
PrP27-30 in the MV 2K cases appears almost invariably
characterized by the association of two PrP
Sc core frag-
ments including a classic 19 kDa type 2 band and a slower
migrating band of about 20 kDa. Although these proﬁles
truly represent concurrent PrP
Sc fragments, and the 20 and
18.5 kDa fragments likely reﬂect speciﬁc PK cleavage sites,
the 20 and 18.5 kDa bands are distinguished from the type 1
and type 2 fragments because, at least to date, they were
never detected independently from types 1 and 2, and are
not markers of speciﬁc clinico-pathological phenotypes.
Knowledge of these regional variations is nonetheless
important to avoid misinterpreting a PrP
Sc proﬁle as novel
when only one brain region is analyzed [21].
Finally, the results obtained from the analyses of lesion
proﬁles and clinical features in the subgroups of sCJD
cases with mixed features deserve further comment. By
showing that the relative ‘‘load’’ of each of the two PrP
Sc
types signiﬁcantly correlates with disease duration, the
relative frequency of certain symptoms, and the ratio
between cortical and cerebellar pathology, our study pro-
vides further strong evidence for the PrP
Sc type being a
major biological determinant in human prion disease.
In conclusion, the present data add to our knowledge of
the prevalence and phenotypic spectrum of the sCJD
variants with mixed molecular and pathological features,
provide an updated molecular classiﬁcation of the disease
subtypes and will serve for future epidemiologic and
transmission studies aimed at disclosing the etiology and
extent of strain variation in sCJD.
Acknowledgments We wish to thank Barbara Polischi and Sabrina
Boninsegna for her technical assistance. We also thank all the phy-
sicians who provided clinical data and helped in the collection of
tissues and all family members who consented to the use of tissue for
research. This study was funded in the frame of the bilateral Italy
(ISS)–USA (NIH, Ofﬁce for Rare Diseases) agreement on joint
research on rare diseases, by the European Commission (FOOD-CT-
2004-506579), the Italian Ministry of University, Research and
Technology (FIRB-2003-RBNE03FMCJ_006), the Federal Ministry
of Health (ZV2-1369-340): grant PHS P30 AG010133, and the Gino
Galletti Foundation.
Conﬂict of interest statement The authors declare that they have
no conﬂict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Baron T, Biacabe AG, Arsac JN, Benestad S, Groschup MH
(2007) Atypical transmissible spongiform encephalopathies
(TSEs) in ruminants. Vaccine 25:5625–5630
2. Barron RM, Thomson V, Jamieson E et al (2001) Changing a
single amino acid in the N-terminus of murine PrP alters TSE
incubation time across three species barriers. EMBO J 20:5070–
5078
3. Bessen RA, Marsh RF (1994) Distinct PrP properties suggest the
molecular basis of strain variation in transmissible mink
encephalopathy. J Virol 68:7859–7868
4. Bolton DC, McKinley MP, Prusiner SB (1982) Identiﬁcation of a
protein that puriﬁes with the scrapie prion. Science 218:1309–
1311
5. Brown P, Coker-Vann M, Pomeroy K et al (1986) Diagnosis of
Creutzfeldt–Jakob disease by Western blot identiﬁcation of
marker protein in human brain tissue. N Engl J Med 314:547–551
6. Bruce ME, McConnell I, Fraser H, Dickinson AG (1991) The
disease characteristics of different strains of scrapie in Sinc
congenic mouse lines: implications for the nature of the agent and
host control of pathogenesis. J Gen Virol 72:595–603
670 Acta Neuropathol (2009) 118:659–671
1237. Cali I, Castellani R, Yuan J et al (2006) Classiﬁcation of sporadic
Creutzfeldt–Jakob disease revisited. Brain 129:2266–2277
8. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey
WS (1991) Secondary structure analysis of the scrapie-associated
protein PrP27–30 in water by infrared spectroscopy. Biochem-
istry 30:7672–7680
9. Caughey B, Raymond GJ, Bessen RA (1998) Strain-dependent
differences in beta-sheet conformations of abnormal prion pro-
tein. J Biol Chem 273:32230–32235
10. Collinge J, Sidle KC, Meads J et al (1996) Molecular analysis of
prion strain variation and the aetiology of ‘new variant’ CJD.
Nature 383:685–690
11. Ferrer I, Armstrong J, Capellari S et al (2007) Effects of formalin
ﬁxation, parafﬁn embedding, and time of storage on DNA pres-
ervation in brain tissue: a BrainNet Europe study. Brain Pathol
17:297–303
12. Goldmann W, Hunter N, Smith G, Foster J, Hope J (1994) PrP
genotype and agent effects in scrapie: change in allelic interaction
with different isolates of agent in sheep, a natural host of scrapie.
J Gen Virol 75:989–995
13. Head MW, Bunn TJ, Bishop MT et al (2004) Prion protein het-
erogeneity in sporadic but not variant Creutzfeldt–Jakob Disease:
U.K. cases. 1991–2002. Ann Neurol 55:851–859
14. Kascsak RJ, Rubenstein R, Merz PA et al (1986) Immunological
comparison of scrapie-associated ﬁbrils isolated from animals
infected with four different scrapie strains. J Virol 59:676–683
15. Kimberlin RH, Cole S, Walker CA (1987) Temporary and per-
manent modiﬁcations to a single strain of mouse scrapie on
transmissions to rats and hamsters. J Gen Virol 68:1875–1881
16. Kobayashi A, Asano M, Mohri S, Kitamoto T (2004) Cross-
sequence transmission of sporadic Creutzfeldt–Jakob disease
creates a new prion strain. J Biol Chem 282:30022–30028
17. Korth C, Kaneko K, Groth D et al (2003) Abbreviated incubation
times for human prions in mice expressing a chimeric mouse-
human prion protein transgene. Proc Natl Acad Sci USA
100:4784–4789
18. Kova ´cs GG, Head MW, Hegyi I et al (2002) Immunohisto-
chemistry for the prion protein: comparison of different
monoclonal antibodies in human prion disease subtypes. Brain
Pathol 12:1–11
19. Kretzschmar H, Giese A, Zerr I et al (1998) The German FFI
cases. Brain Pathol 8:559–561
20. Lewis V, Hill AF, Klug GM, Boyd A, Masters CL, Collins SJ
(2005) Australian sporadic CJD analysis supports endogenous
determinants of molecular-clinical proﬁles. Neurology 65:113–
118
21. Mead S, Joiner S, Desbruslais M et al (2007) Creutzfeldt–Jakob
disease, prion protein gene codon 129VV, and a novel PrP
Sc type
in a young British woman. Arch Neurol 64:1780–1784
22. Monari L, Chen SG, Brown P et al (1994) Fatal Familial
Insomnia and familial Creutzfeldt–Jakob disease: Different prion
proteins determined by a DNA polymorphism. Proc Natl Acad
Sci USA 91:2839–2842
23. Nonno R, Di Bari MA, Cardone F et al (2005) Efﬁcient trans-
mission and characterization of Creutzfeldt–Jakob disease strains
in bank voles. PLoS Pathog 2:e12
24. Notari S, Capellari S, Giese A et al (2004) Effects of different
experimental conditions on the PrP
Sc core generated by protease
digestion. J Biol Chem 279:16797–16804
25. Notari S, Capellari S, Langeveld J et al (2007) A reﬁned method
for molecular typing reveals that co-occurence of PrP
Sc types in
Creutzfeldt–Jakob disease is not the rule. Lab Invest 87:1103–
1112
26. Notari S, Strammiello R, Capellari S et al (2008) Characterization
of truncated forms of abnormal prion protein in Creutzfeldt–
Jakob disease. J Biol Chem 283:30557–30565
27. Pan KM, Baldwin M, Nguyen J et al (1993) Conversion of alpha-
helices into beta-sheets features in the formation of the scrapie
prion proteins. Proc Natl Acad Sci USA 90:10962–10966
28. Parchi P, Castellani R, Capellari S et al (1996) Molecular basis of
phenotypic variability in sporadic Creutzfeldt–Jakob disease. Ann
Neurol 39:767–778
29. Parchi P, Capellari S, Chen SG et al (1997) Typing prion iso-
forms. Nature 386:232–233
30. Parchi P, Giese A, Capellari S et al (1999) Classiﬁcation of
sporadic Creutzfeldt–Jakob disease based on molecular and
phenotypic analysis of 300 subjects. Ann Neurol 46:224–233
31. Parchi P, Capellari S, Chin S et al (1999) A subtype of sporadic
prion disease mimicking fatal familial insomnia. Neurology
52:1757–1763
32. Parchi P, Zou W, Wang W et al (2000) Genetic inﬂuence on the
structural variations of the abnormal prion protein. Proc Natl
Acad Sci USA 97:10168–10172
33. Parchi P, Notari S, Weber P et al (2009) Inter-laboratory
assessment of PrP
Sc typing in Creutzfeldt–Jakob disease: a wes-
tern blot study within the NeuroPrion Consortium. Brain Pathol
19:384–391
34. Pattison IH, Millson GC (1961) Scrapie produced experimentally
in goats with special reference to the clinical syndrome. J Comp
Pathol 71:101–108
35. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi
A (2005) Coexistence of multiple PrP
Sc types in individuals with
Creutzfeldt–Jakob disease. Lancet Neurol 4:805–814
36. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95:13363–
13383
37. Puoti G, Giaccone G, Rossi G, Canciani B, Bugiani O, Tagliavini
F (1999) Sporadic Creutzfeldt–Jakob disease: co-occurrence of
different types of PrP
Sc in the same brain. Neurology 53:2173–
2176
38. Roberts GW, Lofthouse R, Brown R, Crow TJ, Barry RA,
Prusiner SB (1986) Prion protein immunoreactivity in human
transmissible dementias. N Engl J Med 315:1231–1233
39. Safar J, Wille H, Itri V et al (1998) Eight prion strains have PrP
Sc
molecules with different conformations. Nat Med 4:1157–1165
40. Schoch G, Seeger H, Bogousslavsky J et al (2006) Analysis of
prion strains by PrP
Sc proﬁling in sporadic Creutzfeldt–Jakob
disease. PLoS Med 3:e14
41. Somerville RA, Chong A, Mulqueen OU, Birkett CR, Wood SC,
Hope J (1997) Biochemical typing of scrapie strains. Nature
386:564
42. Telling GC, Parchi P, DeArmond SJ et al (1996) Evidence for the
conformation of the pathologic isoform of the prion protein
enciphering and propagating prion diversity. Science 274:2079–
2082
43. Uro-Coste E, Cassard H, Simon S et al (2008) Beyond PrPres
type 1/type 2 dichotomy in Creutzfeldt–Jakob disease. PLoS
Pathog 4:e1000029
44. Yuan J, Dong Z, Guo JP et al (2008) Accessibility of a critical
prion protein region involved in strain recognition and its
implications for the early detection of prions. Cell Mol Life Sci
65:631–643
45. Yull HM, Ritchie DL, Langeveld JP et al (2006) Detection of
type 1 prion protein in variant Creutzfeldt–Jakob disease. Am J
Pathol 168:151–157
Acta Neuropathol (2009) 118:659–671 671
123